Digital Health Global
JANUARY 10, 2024
We are confident that the synergy between TNL’s unique Digital Cell Clones Lab platform and Debiopharm’s profound expertise in drug R&D will show the transformative potential of AI-enabled Digital Labs from disease-target discovery to the optimization of clinical trials.
Digital Health Global
JANUARY 25, 2024
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. from January 23-25, 2024. Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
APRIL 5, 2024
growth between 2023 to 2024. Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.
Digital Health Global
JANUARY 8, 2024
In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.” Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure.
Lloyd Price
FEBRUARY 22, 2024
Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. link] HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Subscribe Today!
Digital Health Global
JANUARY 31, 2024
A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment of on average of $500K in Phase 2 and $1.5M in Phase 3.
Lloyd Price
FEBRUARY 18, 2024
Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! Subscribe Today!
Expert insights. Personalized for you.
88 
Let's personalize your content